Dr. Herbst on a Smoking Cessation Trial for Lung Cancer

Roy S. Herbst, MD, PhD
Published: Tuesday, May 30, 2017



Roy S. Herbst, MD, PhD, ensign professor of Medicine, professor of Pharmacology, chief of Medical Oncology, associate director for Translational Research, Yale Cancer Center and Smilow Cancer Hospital, discusses a smoking cessation trial for patients with lung cancer.

Smoking is the cause of lung cancer in over 80% of patients, explains Herbst. When people come in to be screened it is an important time to discusses the importance of smoking cessation.

It is being investigated if positive reinforcement has more of an impact on a patient looking to quit smoking, states Herbst.
 


Roy S. Herbst, MD, PhD, ensign professor of Medicine, professor of Pharmacology, chief of Medical Oncology, associate director for Translational Research, Yale Cancer Center and Smilow Cancer Hospital, discusses a smoking cessation trial for patients with lung cancer.

Smoking is the cause of lung cancer in over 80% of patients, explains Herbst. When people come in to be screened it is an important time to discusses the importance of smoking cessation.

It is being investigated if positive reinforcement has more of an impact on a patient looking to quit smoking, states Herbst.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ALK-Positive NSCLC: Emerging Strategies to Inform Sequencing, Optimize Outcomes, and Address Unmet Clinical Needs Along the Disease ContinuumAug 29, 20181.5
Community Practice Connections™: Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient OutcomesAug 30, 20182.0
Publication Bottom Border
Border Publication
x